Skip to search formSkip to main contentSkip to account menu

MOR202

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Anti-CD38 Monoclonal Antibody MOR03087

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
ABSTRACT Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall… 
2018
2018
MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation…
Background: CD38 is a type II transmembrane glycoprotein widely expressed in many hematological malignancies including multiple… 
2017
2017
Targeting the crosstalk between tumor cells and microenvironment: a new therapeutic approach for the treatment of lymphoid neoplasms
La senalizacion de los receptores de celulas B (BCR) contribuye a la patogenesis de las neoplasias malignas de celulas B y ha… 
2016
2016
A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Introduction:CD38 is a type II transmembrane glycoprotein widely expressed in many hematological malignancies including multiple… 
2016
2016
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.
8012Background: MOR202, a HuCAL-derived, human IgG1 CD38 monoclonal antibody induces ADCC and ADCP as effector functions… 
2015
2015
A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
8574 Background: MOR202 is a HuCAL-derived fully human IgG1 anti-CD38 antibody, with high efficacy in preclinical models of MM… 
2015
2015
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
Background: CD38 is a type II transmembrane glycoprotein that is expressed at high levels on multiple myeloma cells. MOR202 is a… 
2015
2015
A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma
2014
2014
Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide
Background: MOR202 is a fully human anti-CD38 antibody currently being tested in a Phase I/IIa clinical trial in multiple myeloma… 
2011
2011
Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.
8078 Background: MOR202, a HuCAL-derived fully human anti-CD38 antibody mediates ADCC of multiple myeloma (MM) patient cells with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)